- Home
- UWMC vs XERS Comparison
UWMC vs XERS Comparison
Compare UWMC & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UWMC
- XERS
- Stock Information
- Founded
- UWMC 1986
- XERS 2005
- Country
- UWMC United States
- XERS United States
- Employees
- UWMC N/A
- XERS N/A
- Industry
- UWMC Finance: Consumer Services
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- UWMC Finance
- XERS Health Care
- Exchange
- UWMC Nasdaq
- XERS Nasdaq
- Market Cap
- UWMC 1.4B
- XERS 1.3B
- IPO Year
- UWMC N/A
- XERS 2018
- Fundamental
- Price
- UWMC $5.64
- XERS $9.62
- Analyst Decision
- UWMC Hold
- XERS Strong Buy
- Analyst Count
- UWMC 8
- XERS 7
- Target Price
- UWMC $6.46
- XERS $8.00
- AVG Volume (30 Days)
- UWMC 9.2M
- XERS 2.3M
- Earning Date
- UWMC 11-06-2025
- XERS 11-06-2025
- Dividend Yield
- UWMC 7.09%
- XERS N/A
- EPS Growth
- UWMC 112.84
- XERS N/A
- EPS
- UWMC 0.07
- XERS N/A
- Revenue
- UWMC $2,622,828,000.00
- XERS $246,025,000.00
- Revenue This Year
- UWMC $11.44
- XERS $43.89
- Revenue Next Year
- UWMC $12.48
- XERS $20.40
- P/E Ratio
- UWMC $85.09
- XERS N/A
- Revenue Growth
- UWMC 13.45
- XERS 35.62
- 52 Week Low
- UWMC $3.80
- XERS $2.82
- 52 Week High
- UWMC $7.14
- XERS $10.03
- Technical
- Relative Strength Index (RSI)
- UWMC 46.50
- XERS 70.04
- Support Level
- UWMC $5.19
- XERS $9.11
- Resistance Level
- UWMC $5.95
- XERS $9.49
- Average True Range (ATR)
- UWMC 0.20
- XERS 0.41
- MACD
- UWMC 0.04
- XERS 0.04
- Stochastic Oscillator
- UWMC 60.00
- XERS 82.00
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).